Research and Trials

Cancer 01 Jan 2013

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities

Advanced colorectal cancer. To establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. Official Title Conditions Study Type…
Blood 01 Jan 2013

Transfusion Medicine/Hemostasis Clinical Research Network

To establish a clinical network which will promote the efficient comparison of new management strategies of potential benefit for children and adults with hemostatic disorders such as idiopathic thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP). The network also will evaluate new as well as existing blood products and cytokines for…
Infections 01 Jan 2013

Tifacogin for the Treatment of Patients with Severe Community-Acquired Pneumonia

The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia. Official Title Tifacogin (recombinant tissue factor pathway inhibitor) for the Treatment of Patients with Severe Community-Acquired Pneumonia Conditions Pneumonia Study Type Interventional Study Design Treatment Further Details…
Cancer 01 Jan 2013

Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor

RATIONALE: Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining sulindac with tamoxifen may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining…
Heart 01 Jan 2013

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II. Official Title A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability…
Cancer 01 Jan 2013

Treatment of non-Hodgkin’s lymphoma with rituximab plus CHOP chemotherapy: 9-year follow-up

The objective of the study was to present long-term follow-up data with updated time to disease progression (TTP) and duration of response (DR) from a multicenter, phase II trial of R-CHOP combination therapy in 40 patients with CD20+, B-cell NHL. Primary endpoints: ORR, PR rate and CR rate; secondary endpoints:…
Pain and Stress Management for People with Rheumatoid Arthritis
Chronic Pain 01 Jan 2013

Pain and Stress Management for People with Rheumatoid Arthritis

Self-management of rheumatoid arthritis (RA) symptoms using written emotional disclosure (ED), coping skills training (CST), or a combination of both may benefit people with RA. The purpose of this study is to determine the benefits of ED, CST, or CST and ED together in adults with RA. This study will…
Levosimendan versus Dobutamine in Shock Patients
Blood 01 Jan 2013

Levosimendan versus Dobutamine in Shock Patients

The purpose of the study is to compare the efficacy of levosimendan with that of dobutamine in patients with unstable hemodynamics (shock). Official Title Efficacy of Levosimendan in the Critically Ill Patients with Unstable Hemodynamics (the LICI study) – A Double Blind Randomized Pilot Study Conditions – Cardiogenic Shock-…
Joints 01 Jan 2013

Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Ankylosing Spondylitis

The objective of this study is to evaluate the safety and efficacy of adalimumab 40mg every other week (eow) compared to placebo in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAID) and who may have…